Neurosurgical Review

, Volume 17, Issue 3, pp 211–215 | Cite as

Association of malignant glioma with the human leukocyte antigen, HLA-A24(9)

  • Taizo Nitta
  • Michimasa Ebato
  • Kiyoshi Sato


Many immune responses are controlled by genes of the major histocompatibility complex (MHC). In humans these include the loci encoding the HLA-A,-B,-C,-DR,-DQ and-DP antigens, and many diseases have been linked with these. However, little information is available about any connection between malignant tumors and HLA. In this study the possible association of HLA-A,-B,-C and-DR specificities with susceptibilitities to malignant glioma was investigated in 42 patients with malignant glioma and 42 controls with non-glial intracranial tumors using the Terasaki-NIH standard method. The data were also compared with those of the 11th International HLA Workshop. The result showed that a high frequency of HLA-24(9) was observed in patients with intracranial malignant gliomas, which was not common in other, non-glial patient groups. In animals the MHC acts in defense against virally induced tumors, but until now there has been no evidence that they do so in human gliomas. Our discovery of its association with an HLA antigen is important for understanding the immunogenetic basis of susceptibility to glioma.


Human leukocyte antigen major histocompatibility complex malignant glioma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Apuzzo MLJ, MS Mitchell: Immunobiological aspects of intrinsic glial tumors. J Neurosurg 55 (1981) 1–18Google Scholar
  2. [2]
    Benjamin R, P Parham: Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 11 (1990) 137–139Google Scholar
  3. [3]
    Blackman MA, JW Kappler, P Marrack: T-cell specificity and repertoire. Immunol Rev 101 (1988) 5–19Google Scholar
  4. [4]
    Burger PC, SB Green: Patient age, histological features and length of survival in patients with glioblastoma multiforme. Cancer 59 (1987) 1617–1625Google Scholar
  5. [5]
    Ebato M, T Nitta, H Yagita, K Sato, K Okumura: Skewed distribution of TCR Vα-bearing T cells within tumor-infiltrating lymphocytes of HLA-A24(9)-positive patients with malignant glioma. Immunol Lett 39 (1994) 53–64Google Scholar
  6. [6]
    Itoh K, CD Platsoucas, CM Balch: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. J Exp Med 168 (1988) 1419–1441Google Scholar
  7. [7]
    Kampgen E, G Burz, R Wank: Association of herpes simplex virus-induced erythema multiforme with the human leukocyte antigen DGw3. Arch Dermatol 124 (1988) 1372–1375Google Scholar
  8. [8]
    Koenig UD, N Muller, KE Schneweis: Herpessimplex type-2 antibodies and HLA-B12 in cervical cancer. Lancet ii (1976) 857Google Scholar
  9. [9]
    Lopez de Castro JA: HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol Today 10 (1989) 239–246Google Scholar
  10. [10]
    Marrack P, J Kappler: The T cell receptor. Science 238 (1987) 1073Google Scholar
  11. [11]
    Miceli MC, OJ Finn: cell receptor β-chain selection in human allograft rejection. J Immunol 142 (1989) 81–86Google Scholar
  12. [12]
    Muul LM; PJ Spiess, EP Director, SA Rosenberg: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant glioma. J Immunol 138 (1987) 989–995Google Scholar
  13. [13]
    Nitta T, JR Oksenberg, NA Rao, L Steinman: Predominant expression of T cell receptor Vα7 in tumor infiltrating lymphocytes of uveal melanoma. Science 249 (1990) 672–674Google Scholar
  14. [14]
    Nitta T, K Sato, H Yagita, K Okumura, S Ishii: Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335 (1990) 368–370Google Scholar
  15. [15]
    Panza NL, D Vecchio, M Maio, MD Felice, G Lombardi, M Minozzi, S Zappacosta: Tissue Antigen 20 (1992) 155–164Google Scholar
  16. [16]
    Riley E, O Olerup: HLA polymorphisms and evolution. Immunol Today 13 (1992) 333–335Google Scholar
  17. [17]
    Rittner G, G Schwanitz, MP Baur, CM Black, KI Welsh, P Kuhnl, C Rittner: Family studies in scleroderma demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet 81 (1988) 64–70Google Scholar
  18. [18]
    Rosenberg SA: The development of new immunotherapies for the treatment of cancer using Interleukin-2. Ann Surg 208 (1988) 121–135Google Scholar
  19. [19]
    Rosenberg SA, P Spiess, R Lafrieniere: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 (1986) 1318–1321Google Scholar
  20. [20]
    Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 12 (1982) 231–237Google Scholar
  21. [21]
    Takasugi M, PI Terasaki, B Henderson, MR Mickey, H Menck, RW Thompson: HLA-antigens in solid tumors. Cancer Res 33 (1973) 648–650Google Scholar
  22. [22]
    Terasaki PI, JD McClelland: Microdroplet assay of human serum cytotoxins. Nature 204 (1964) 998–1000Google Scholar
  23. [23]
    Terasaki PI, D Bernoco, MS Park, G Ozuturk, Y Iwaki: Microdroplet testing for HLA-A,-B,-C and-D antigens. Am J Clin Pathol 69 (1978) 103–118Google Scholar
  24. [24]
    Tsuji K, M Aizawa, T Sasazuki: HLA 1991, Proceeding of the 11th International Histocompatibility Workshop and Conference. Oxford Science Publications, W15.1 (1991) 1067–1166Google Scholar
  25. [25]
    Wank R, C Thomssen: High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 352 (1990) 723–725Google Scholar
  26. [26]
    Weiss EH, A Ziegler: HLA-genes and function. Immunol Today 19 (1989) 516–518Google Scholar
  27. [27]
    Winoto A, JL Urban, NC Lan, J Goverman, L Hood, D Hansburg: Predominant use of a Vα gene segment in mouse T-cell receptors for cytochrome c. Nature 324 (1986) 679–682Google Scholar
  28. [28]
    Zulch KJ: Histological typing of tumors of the central nervous system. Geneva; Wordl Health Organization (1979) pp 160–172Google Scholar

Copyright information

© Walter de Gruyter & Co. 1994

Authors and Affiliations

  • Taizo Nitta
    • 1
  • Michimasa Ebato
    • 1
  • Kiyoshi Sato
    • 1
  1. 1.Department of NeurosurgeryJuntendo University School of MedicineTokyoJapan

Personalised recommendations